Proposed Prognostic Model for CNS Risk in Aggressive B-Cell Lymphoma Validated
Investigators validated the German High-Grade Non-Hodgkin Lymphoma Study Group’s new prognostic model for aggressive B-cell lymphoma.
Investigators validated the German High-Grade Non-Hodgkin Lymphoma Study Group’s new prognostic model for aggressive B-cell lymphoma.
Addition of radiotherapy should be reserved for the minority of patients with non-bulky limited-stage diffuse large B cell lymphoma (DLBCL).
Pomalidomide, bortezomib, and dexamethasone is a highly effective combination in multiple myeloma refractory to lenalidomide.
CTL019 cells cause strong, durable responses in pediatric patients with relapsed, refractory acute lymphocytic leukemia (ALL).
Patients with classical Hodgkin lymphoma (cHL) who were heavily pretreated had clinical benefit from pembrolizumab (MK-3475).
Pacritinib suppresses leukemic outgrowth from stroma-adherent cells in FLT3-ITD-driven acute myeloid leukemia (AML).
Multiple myeloma patients who received once-weekly carfilzomib with cyclophosphamide, dexamethasone had improved responses.
The largest study of T-lymphoblastic leukemia (T-ALL) ever conducted demonstrated “an excellent outcome” with standard four-drug induction.
Rituximab should be used as maintenance therapy for the treatment of young previously untreated patients with mantle cell lymphoma.
Lenalidomide induces the ubiquitination and degredation of casein kinase 1A1 (CSNK1A1) by the CRBN-CRL4 E3 ubquitin ligase.